Alvogen Patent-Cliff Exposure & CMS Drug Spending Portfolio

Alvogen (US): 6 reconciled FDA prescription therapies, $177.9M 2024 CMS Part D & Medicaid spend, and $2,599 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies6
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$177.9M
2024 Medicare Part D Spend$136.5M
2024 Medicaid Spend$41.4M
California HCAI SB 17 FilingsSpecialty launch notice ($2,599 intro WAC)